Nu Skin (NUS) Q2 2026 Earnings Report

The call presented a mixed picture: strong product momentum and engagement around Prysm iO, improved core gross margin, cost reductions in G&A, and disciplined liquidity position are notable positives. However, sizable non-cash goodwill and deferred tax charges materially impacted reported earnings, adjusted operating margins declined, recruiting and leadership development remain weak, and the India launch was delayed. Near-term FX headwinds and modest operating cash flow further temper the outlook. On balance, the company shows encouraging strategic traction and product adoption but faces meaningful near-term financial and operational headwinds.

Nu Skin updated Q3 revenue guidance to $310–$340 million (with an expected 2–3% foreign currency headwind) and Q3 EPS of $0.00–$0.09 reported (adjusted $0.10–$0.20), and revised full‑year revenue to $1.28–$1.35 billion (≈1% FX headwind) with reported FY EPS of −$4.90 to −$4.73 (adjusted $0.70–$0.90) and an adjusted effective tax rate of ~35%; management expects to place 50,000–60,000 Prysm iO devices by year‑end (vs. >39,000 placed to date, up ~30% QoQ, and 2.5 million scans, up ~25% QoQ). The company plans $5–$10 million of cash‑based organizational transition costs through year‑end excluded from adjusted results and also excluded the Q2 non‑cash charges (a $78.9M goodwill impairment and a $167.5M deferred tax valuation allowance) from adjusted guidance; for context Q2 revenue was $320.1M, gross margin 68.2% (core 77.7%), adjusted operating margin 6.1%, cash $189.6M, debt $213.7M and Q2 operating cash flow $10.6M.